Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cash, Lights, Go: Shanghai Takes On Boston In Latest Policy Appeal To Biopharma

From R&D To Manufacturing Powerhouse?

Executive Summary

Developers of antibodies, novel vaccines and cell and gene therapies are all slated to get funding support as Shanghai unleashes a flurry of incentives and policies to lead China’s push to become a global biopharma powerhouse.

You may also be interested in...



BeyondSpring's Next Move Uncertain After Plinabulin CRL

Chinese firm BeyondSpring dealt a setback after the US FDA refuses to approve plinabulin for chemotherapy-induced neutropenia.

China mRNA Player Abogen Gets $300m More As Country Eyes Omicron Threat

From inactivated virus-based to mRNA platforms, the race is on in China to develop vaccines to fight the latest omicron variant, with substantial new funding pouring into one young mRNA company.

3D Med, Alphamab Get First SubQ Immuno-Oncology Approval, In China

A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.

Topics

Related Companies

UsernamePublicRestriction

Register

PS144367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel